Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN2 in Refractory Liver Tumors
NCT04313868Phase 1Completed
- Sponsor
- GenVivo
- Start
- Jun 2014
- Primary completion
- Dec 2023
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label trial of GEN2 in hepatocellular carcinoma (HCC) and liver metastases (3 arms), sponsored by GenVivo. Primary endpoints: Maximum Tolerated Dose at 3 weeks, Dose Limiting Toxicity at 3 weeks and 2 more. Started Jun 2014; status: completed.
02
Drugs
GEN2
03
Conditions
hepatocellular carcinoma (HCC)liver metastases
Beyond the preview
Go deeper on NCT04313868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04313868.